Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Affecting two to three percent of the global population, psoriasis should be viewed for what it is: a serious systemic ...

“Biologics” are game-changing new treatments transforming the lives of people with psoriasis and psoriatic arthritis by clearing their skin, healing their joints, and reducing potentially irreversible ...

In a combined network meta-analysis, infliximab and adalimumab had the greatest risk for serious infection in patients with plaque psoriasis.

The ustekinumab (Stelara; Janssen Biotech) biosimilar DMB-3115 (Imuldosa; Accord BioPharma) demonstrated clinical efficacy and safety comparable to the reference product through 52 weeks in a recent ...

A potential for cumulative life course impairment is not completely considered in clinical practice, driving the ...

The treatment of psoriasis—an autoimmune disease that creates red, scaly plaques on the skin—depends on multiple factors, but two big factors include the severity and the location of the symptoms, ...

Psoriasis is a lifelong condition that comes and goes in flares, and the key to managing it is the right treatment. Your dermatologist will help you find a therapy based on: How bad your symptoms are ...

A German multicentre study reveals strong patient demand for systemic therapy in atopic dermatitis and psoriasis. Learn more about treatment preferences and drivers.

Itchy, flaky psoriasis is never fun, but it can also sometimes be downright painful. Working with your derm to find the right treatment option is crucial, but with so many potential options to choose ...

Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J., Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ...